Key Takeaways from ACC.25 Major Trials and Presentations
In this week’s View, Dr. Eagle looks at the major trials and presentations from the recently concluded ACC.25 in Chicago. This episode includes coverage of practice-changing and practice-validating trials including: Evolut Low Risk: Transcatheter aortic valve replacement (TAVR) noninferior to surgical aortic valve replacement (SAVR) at 5-Year Follow-Up SMART-CHOICE 3: Clopidogrel shows benefit over aspirin monotherapy following percutaneous coronary intervention (PCI) DAPA-TAVI: Dapagliflozin safe and effective in older adults with heart failure (HF) undergoing transcatheter aortic valve implantation (TAVI) STRIDE: Semaglutide improves peripheral artery disease (PAD) outcomes RIVAWAR: Rivaroxaban as effective as warfarin for post-myocardial infarction (MI) left ventricle (LV) thrombus API-CAT: Extended anticoagulant therapy with reduced-dose apixaban noninferior to full-dose in patients with active cancer and venous thromboembolism (VTE) Subscribe to Eagle’s Eye View
In this week’s View, Dr. Eagle looks at the latest clinical guidance on the management of cardiogenic shock. He then discusses trends in mortality after mitral repair and TAVR. Finally, Dr. Eagle offers a brief exploration into how direct-to-physician industry marketing affects rates of guideline-directed medical therapy (GDMT) surrounding heart failure patients. Subscribe to Eagle’s Eye View
--------
7:55
Smoking & CVD Risk; Sleep, Diabetes, & Women with Gestational Diabetes; Post-TAVR Imaging
In this week’s View, Dr. Eagle examines the dose-response relationship between smoking and subclinical cardiovascular disease markers. He then discusses how the effect of poor sleep increases diabetes risk in women who have had gestational diabetes. Finally, Dr. Eagle offers a look into imaging post-transcatheter aortic valve replacement (TAVR) in patients who may have valve failure. Subscribe to Eagle’s Eye View
--------
7:01
Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin & Heart Failure; Non-Pharmacologic Treatment of HF
In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients. Subscribe to Eagle’s Eye View
--------
6:56
Identifying Myocardial Infarction after PCI; Myocardial Fibrosis & Severe Aortic Valve Stenosis; Anticoagulation & Cancer Diagnoses
In this week’s View, Dr. Eagle looks at the optimal threshold for identifying a myocardial infarction (MI) after PCI. He then discusses myocardial fibrosis and its prognostic features in patients undergoing treatment for severe aortic valve stenosis. Finally, Dr. Eagle explores the relationship between bleeding after initiation of anticoagulation and cancer diagnoses. Subscribe to Eagle’s Eye View
Acerca de Eagle's Eye View: Your Weekly CV Update From ACC.org
The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
España